Partial
Mostly Aligned
Patient Risk:
Medium
Summary
The specific indication/symptom-improvement claim for mastocytosis is supported by the label, but multiple other claims extend beyond the provided label text (e.g., other mast cell disorders/activation disorders, general mediator/histamine effects on symptoms, marketing/availability statements) and are not supported by the supplied prescribing information.
Category Scores
Accurate Statements
GASTROCROM is indicated in the management of patients with mastocytosis and may improve symptoms including diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients.
INDICATIONS AND USAGE: “GASTROCROM is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients.”
Cromolyn sodium inhibits the release of mediators from sensitized mast cells and inhibits release of histamine and leukotrienes (SRS-A) from mast cells.
CLINICAL PHARMACOLOGY: “cromolyn sodium inhibits the release of mediators from sensitized mast cells… inhibits the release of histamine and leukotrienes (SRS-A) from the mast cell.”
Unsupported Statements
Gastrocrom is a brand name for cromolyn sodium.
The supplied label excerpts do not explicitly state that Gastrocrom is the brand name for cromolyn sodium.
Gastrocrom is a prescription medicine.
The supplied label excerpts do not explicitly state it is prescription-only.
Gastrocrom is used to help prevent and treat symptoms related to mast cell disorders.
The provided INDICATIONS AND USAGE text specifies mastocytosis; it does not state “prevent and treat symptoms related to mast cell disorders” broadly.
Stabilizing mast cells reduces the release of substances such as histamine.
The provided label excerpt supports inhibition of mediator release (histamine/leukotrienes), but it does not use the phrasing “stabilizing mast cells reduces…” in the supplied text.
Reduced histamine release can reduce symptoms such as stomach pain, diarrhea, and flushing in some conditions.
The label excerpt associates improvement in diarrhea and flushing with use in mastocytosis, but it does not make a generalized causal statement linking reduced histamine release to those symptoms “in some conditions” beyond the provided indication language.
Gastrocrom is most commonly associated with treatment of gastrointestinal symptoms in mast cell–related conditions.
The supplied label excerpt does not address frequency/commonality or “most commonly associated” GI-only use.
Gastrocrom is used in mast cell–related conditions such as mastocytosis and other mast cell activation disorders.
The provided INDICATIONS AND USAGE excerpt limits indication to mastocytosis; no mention of “mast cell activation disorders” is included.
Mast cell mediator release in mast cell disorders can cause recurring gastrointestinal problems.
The supplied label excerpt does not state that mediator release causes recurring GI problems.
Cromolyn sodium is a mast cell stabilizer.
The supplied label excerpt describes inhibition of mediator release but does not explicitly call cromolyn sodium a “mast cell stabilizer.”
By stabilizing mast cells, cromolyn sodium helps reduce mediator release that can cause inflammatory and allergy-like symptoms.
The supplied label excerpt does not describe “inflammatory and allergy-like symptoms” or use this framing.
The mediator release reduced by cromolyn sodium can include gastrointestinal manifestations in mast cell disorders.
The label excerpt lists symptom improvements in mastocytosis (including abdominal pain/nausea/diarrhea) but does not support the broader statement connecting “mediator release reduced” to “gastrointestinal manifestations in mast cell disorders” in general.
Gastrocrom is marketed by a manufacturer that appears in drug market/patent tracking sources.
The supplied label excerpts do not include marketing/manufacturer information or references to drug market/patent tracking sources.
Gastrocrom availability can vary by country.
The supplied label excerpts do not address country-by-country availability.
Gastrocrom availability can vary depending on whether the product is still being produced or substituted with generics or alternatives.
The supplied label excerpts do not address manufacturing status, generic substitution, or availability changes.
As with any prescription medicine, patients should follow the prescribing doctor’s instructions for dosing and duration.
The provided label excerpts do not include this general instruction (and it is not directly supported by the included text).
Gastrocrom is typically used for conditions where mast cells are a known driver of symptoms, particularly GI symptoms tied to mediator release.
The supplied label excerpt does not support “typically used” language, nor does it characterize indications as “mast cells are a known driver” or focus on GI symptoms “tied to mediator release.”
Contradictions
Important Omissions
Administration/dosing instructions (e.g., route/formulation details and specific dosing regimen) for Gastrocrom.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims broaden indication scope beyond mastocytosis (e.g., “mast cell activation disorders” and general mast cell disorders/GI symptoms), which could misrepresent labeled use. Other unsupported generalizations are less directly safety-critical but may affect understanding of appropriate labeled indication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims are not supported by the supplied prescribing information, particularly those expanding the indication beyond mastocytosis and those asserting specific causal mechanisms/symptom links beyond the label’s wording.
Suggested Improvement
Restrict indication-related statements to “mastocytosis” and align mechanism/symptom wording to the provided label language (mediator release inhibition; associated improvement in listed symptoms in some patients). Remove or qualify unsupported statements about brand/manufacturer, availability by country, and generalized dosing adherence.